Monday - February 2, 2026
European Commission Approves Roche's Gazyva/Gazyvaro for Adults With Active Lupus Nephritis
December 09, 2025
BASEL, Switzerland, Dec. 9 -- Roche, a biotech company, issued the following news release:

* * *

European Commission approves Roche's Gazyva/Gazyvaro for adults with active lupus nephritis

Approval based on phase II NOBILITY and phase III REGENCY studies showing superiority of Gazyva/Gazyvaro over standard therapy alone/1,2

Gazyva/Gazyvaro is the only anti-CD20 antibody to demonstrate a benefit in a complete renal response in lupus nephrit . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products